Chief Financial Officer and Head of Corporate Development
Yasir Al-Wakeel joined Kronos Bio in 2020 as Chief Financial Officer and Head of Corporate Development. Prior to joining Kronos Bio, Yasir was Chief Financial and Strategy Officer at Neon Therapeutics since 2017, where he played a key role in the company’s public and private financings as well as its eventual sale to BioNTech. From 2015 – 2017, he was Chief Financial Officer and Head of Corporate Development at Merrimack Pharmaceuticals, where he helped shape and execute the company’s refocused business strategy, culminating in a $1 billion asset sale to Ipsen. Previously, Yasir served in senior roles in equity research and corporate finance at Credit Suisse focused on the biotechnology sector. During his tenure in corporate finance, he was involved in more than $30 billion in strategic and financial transactions for the firm. Yasir began his career as a practicing physician, holding both clinical and academic medical posts in the United Kingdom before his roles in finance and early-stage biotechnology. Yasir received his BM BCh (Doctor of Medicine and Surgery) from Oxford University and an M.A. in theology from Cambridge University.